Uwe Reusch - JoVE Visualize

Search research articles

ABOUT JoVE

Overview Leadership Blog JoVE Help Center

AUTHORS

Publishing Process Editorial Board Scope & Policies Peer Review FAQ Submit

LIBRARIANS

Testimonials Subscriptions Access Resources Library Advisory Board FAQ

RESEARCH

JoVE Journal Methods Collections JoVE Encyclopedia of Experiments Archive

EDUCATION

JoVE Core JoVE Business JoVE Science Education JoVE Lab Manual Faculty Resource Center Faculty Site

Terms & Conditions of Use

Policies

Search research articles

ABOUT JoVE

Overview Leadership Blog JoVE Help Center

AUTHORS

Publishing Process Editorial Board Scope & Policies Peer Review FAQ Submit

LIBRARIANS

Testimonials Subscriptions Access Resources Library Advisory Board FAQ

RESEARCH

JoVE Journal Methods Collections JoVE Encyclopedia of Experiments Archive

EDUCATION

JoVE Core JoVE Business JoVE Science Education JoVE Lab Manual Faculty Resource Center Faculty Site

Terms & Conditions of Use

Policies

Filters

Uwe Reusch

Showing results (31-40 of 36) with videos related to

Pageof 4

Sort By:

You have reached the last page of results.This site can display upto 36 results.

Mabs|April 16, 2015

A tetravalent bispecific TandAb (CD19/CD3), AFM11, efficiently recruits T cells for the potent lysis of CD19(+) tumor cellsUwe Reusch, Johannes Duell, Kristina Ellwanger, et al.

Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|May 19, 2016

Characterization of CD33/CD3 Tetravalent Bispecific Tandem Diabodies (TandAbs) for the Treatment of Acute Myeloid LeukemiaUwe Reusch, Kimberly H Harrington, Chelsea J Gudgeon, et al.

Journal of Molecular Biology|April 5, 2008

Invasion of tumorigenic HT1080 cells is impeded by blocking or downregulating the 37-kDa/67-kDa laminin receptorChantal Zuber, Stefan Knackmuss, Georgeta Zemora, et al.

Mabs|July 30, 2021

Preclinical evaluation of AFM24, a novel CD16A-specific innate immune cell engager targeting EGFR-positive tumorsSusanne Wingert, Uwe Reusch, Stefan Knackmuss, et al.

Nature Communications|August 21, 2025

The bispecific innate cell engager AFM28 eliminates CD123<sup>+</sup> leukemic stem and progenitor cells in AML and MDSNanni Schmitt, Jana-Julia Siegler, Alexandra Beck, et al.

Leukemia|January 10, 2022

A BCMA/CD16A bispecific innate cell engager for the treatment of multiple myelomaSatoko Kakiuchi-Kiyota, Thorsten Ross, Heidi Ackerly Wallweber, et al.

Pageof 4

Search research articles

Showing results (31-40 of 36) with videos related to

Sort By:

Pageof 4

You have reached the last page of results.This site can display upto 36 results.

Mabs|April 16, 2015

A tetravalent bispecific TandAb (CD19/CD3), AFM11, efficiently recruits T cells for the potent lysis of CD19(+) tumor cellsUwe Reusch, Johannes Duell, Kristina Ellwanger, et al.

Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|May 19, 2016

Characterization of CD33/CD3 Tetravalent Bispecific Tandem Diabodies (TandAbs) for the Treatment of Acute Myeloid LeukemiaUwe Reusch, Kimberly H Harrington, Chelsea J Gudgeon, et al.

Journal of Molecular Biology|April 5, 2008

Invasion of tumorigenic HT1080 cells is impeded by blocking or downregulating the 37-kDa/67-kDa laminin receptorChantal Zuber, Stefan Knackmuss, Georgeta Zemora, et al.

Mabs|July 30, 2021

Preclinical evaluation of AFM24, a novel CD16A-specific innate immune cell engager targeting EGFR-positive tumorsSusanne Wingert, Uwe Reusch, Stefan Knackmuss, et al.

Nature Communications|August 21, 2025

The bispecific innate cell engager AFM28 eliminates CD123<sup>+</sup> leukemic stem and progenitor cells in AML and MDSNanni Schmitt, Jana-Julia Siegler, Alexandra Beck, et al.

Leukemia|January 10, 2022

A BCMA/CD16A bispecific innate cell engager for the treatment of multiple myelomaSatoko Kakiuchi-Kiyota, Thorsten Ross, Heidi Ackerly Wallweber, et al.

Pageof 4